390 related articles for article (PubMed ID: 34131404)
21. TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling.
Li S; Bode AM; Zhu F; Liu K; Zhang J; Kim MO; Reddy K; Zykova T; Ma WY; Carper AL; Langfald AK; Dong Z
Carcinogenesis; 2011 May; 32(5):779-85. PubMed ID: 21349818
[TBL] [Abstract][Full Text] [Related]
22. TRPing the switch on pain: an introduction to the chemistry and biology of capsaicin and TRPV1.
Conway SJ
Chem Soc Rev; 2008 Aug; 37(8):1530-45. PubMed ID: 18648679
[TBL] [Abstract][Full Text] [Related]
23. Modulation of human TRPV1 receptor activity by extracellular protons and host cell expression system.
Bianchi BR; Lee CH; Jarvis MF; El Kouhen R; Moreland RB; Faltynek CR; Puttfarcken PS
Eur J Pharmacol; 2006 May; 537(1-3):20-30. PubMed ID: 16630609
[TBL] [Abstract][Full Text] [Related]
24. The ion channel TRPV1 gain-of-function reprograms the immune microenvironment to facilitate colorectal tumorigenesis.
Jiang X; Wang C; Ke Z; Duo L; Wu T; Wang W; Yang Y; Dai Y
Cancer Lett; 2022 Feb; 527():95-106. PubMed ID: 34920021
[TBL] [Abstract][Full Text] [Related]
25. Transient receptor potential cation channel subfamily V and breast cancer.
So CL; Milevskiy MJG; Monteith GR
Lab Invest; 2020 Feb; 100(2):199-206. PubMed ID: 31822791
[TBL] [Abstract][Full Text] [Related]
26. A patent review of transient receptor potential vanilloid type 1 modulators (2014-present).
Gao M; Wang Y; Liu L; Qiao Z; Yan L
Expert Opin Ther Pat; 2021 Feb; 31(2):169-187. PubMed ID: 33377418
[No Abstract] [Full Text] [Related]
27. Direct evidence for functional TRPV1/TRPA1 heteromers.
Fischer MJ; Balasuriya D; Jeggle P; Goetze TA; McNaughton PA; Reeh PW; Edwardson JM
Pflugers Arch; 2014 Dec; 466(12):2229-41. PubMed ID: 24643480
[TBL] [Abstract][Full Text] [Related]
28. "TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure".
Horton JS; Shiraishi T; Alfulaij N; Small-Howard AL; Turner HC; Kurokawa T; Mori Y; Stokes AJ
Channels (Austin); 2019 Dec; 13(1):1-16. PubMed ID: 30424709
[TBL] [Abstract][Full Text] [Related]
29. Analgesic transient receptor potential vanilloid-1-active compounds inhibit native and recombinant T-type calcium channels.
McArthur JR; Finol-Urdaneta RK; Adams DJ
Br J Pharmacol; 2019 Jul; 176(13):2264-2278. PubMed ID: 30927254
[TBL] [Abstract][Full Text] [Related]
30. Capsaicin receptor: TRPV1 a promiscuous TRP channel.
Pingle SC; Matta JA; Ahern GP
Handb Exp Pharmacol; 2007; (179):155-71. PubMed ID: 17217056
[TBL] [Abstract][Full Text] [Related]
31. Recent progress in the development of selective TRPV1 antagonists for pain.
Broad LM; Keding SJ; Blanco MJ
Curr Top Med Chem; 2008; 8(16):1431-41. PubMed ID: 18991729
[TBL] [Abstract][Full Text] [Related]
32. Possible consequences of blocking transient receptor potential vanilloid.
Bishnoi M; Premkumar LS
Curr Pharm Biotechnol; 2011 Jan; 12(1):102-14. PubMed ID: 20932252
[TBL] [Abstract][Full Text] [Related]
33. Targeting TRPV1 for pain relief: limits, losers and laurels.
Szallasi A; Sheta M
Expert Opin Investig Drugs; 2012 Sep; 21(9):1351-69. PubMed ID: 22780443
[TBL] [Abstract][Full Text] [Related]
34. Activation of TRPV1 and TRPA1 by black pepper components.
Okumura Y; Narukawa M; Iwasaki Y; Ishikawa A; Matsuda H; Yoshikawa M; Watanabe T
Biosci Biotechnol Biochem; 2010; 74(5):1068-72. PubMed ID: 20460725
[TBL] [Abstract][Full Text] [Related]
35. Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin.
Maiese K
Curr Neurovasc Res; 2017; 14(2):184-189. PubMed ID: 28294062
[TBL] [Abstract][Full Text] [Related]
36. Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels.
Nazıroğlu M; Çiğ B; Blum W; Vizler C; Buhala A; Marton A; Katona R; Jósvay K; Schwaller B; Oláh Z; Pecze L
PLoS One; 2017; 12(6):e0179950. PubMed ID: 28640864
[TBL] [Abstract][Full Text] [Related]
37. Differential modulation of agonist and antagonist structure activity relations for rat TRPV1 by cyclosporin A and other protein phosphatase inhibitors.
Pearce LV; Toth A; Ryu H; Kang DW; Choi HK; Jin MK; Lee J; Blumberg PM
Naunyn Schmiedebergs Arch Pharmacol; 2008 Apr; 377(2):149-57. PubMed ID: 18259730
[TBL] [Abstract][Full Text] [Related]
38. TRPV1 antagonists as a potential treatment for hyperalgesia.
Roberts LA; Connor M
Recent Pat CNS Drug Discov; 2006 Jan; 1(1):65-76. PubMed ID: 18221192
[TBL] [Abstract][Full Text] [Related]
39. Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).
Lee Y; Hong S; Cui M; Sharma PK; Lee J; Choi S
Expert Opin Ther Pat; 2015 Mar; 25(3):291-318. PubMed ID: 25666693
[TBL] [Abstract][Full Text] [Related]
40. Impact of TRPV1 on Pathogenesis and Therapy of Neurodegenerative Diseases.
Wang W; Sun T
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
